celecoxib has been researched along with Reperfusion Injury in 19 studies
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib beneficially affects the outcome of renal IRI by lowering the expression of COX-2 and hence reducing oxidative stress and increasing the bioavailability of NO." | 5.40 | Celecoxib modulates nitric oxide and reactive oxygen species in kidney ischemia/reperfusion injury and rat aorta model of hypoxia/reoxygenation. ( AbdelMoneim, L; Omar, AG; Senbel, AM, 2014) |
| " Nitric oxide (NO) precursors, especially l-arginine, may have protective effects on tissue ischemia/reperfusion injury (IRI); however, their molecular mechanisms are unclear." | 3.80 | Evaluation of l-arginine on kidney function and vascular reactivity following ischemic injury in rats: protective effects and potential interactions. ( Abdel-Moneim, LM; Daabees, TT; Mohamed, HF; Omar, AG; Senbel, AM, 2014) |
| " Celecoxib (10, 20 and 40 mg/kg(-l)) was significantly more potent at aggravating ischemia-reperfusion injury as compared to nimesulide." | 3.73 | Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors. ( Malhotra, S; Nada, R; Pandhi, P; Shafiq, N, 2005) |
| " Whether the chronic administration of HMG-CoA reductase inhibitors provides similar protection remains controversial and is unknown in humans." | 2.77 | Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study. ( Gori, T; Liuni, A; Luca, MC; Parker, JD, 2012) |
| "Celecoxib treatment improved the neurologic deficit, reduced the infarct volume by 50% after 48 hours of reperfusion, and resulted in a reduced percentage of SNL areas and microglia and astroglia reactivity after 48 hours of reperfusion." | 1.48 | Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion. ( Anuncibay-Soto, B; Fernández-López, A; Font-Belmonte, E; Pérez-García, CC; Pérez-Rodríguez, D; Santos-Galdiano, M; Ugidos, IF, 2018) |
| "Celecoxib beneficially affects the outcome of renal IRI by lowering the expression of COX-2 and hence reducing oxidative stress and increasing the bioavailability of NO." | 1.40 | Celecoxib modulates nitric oxide and reactive oxygen species in kidney ischemia/reperfusion injury and rat aorta model of hypoxia/reoxygenation. ( AbdelMoneim, L; Omar, AG; Senbel, AM, 2014) |
| " The present study investigated the importance of endogenous prostaglandin production and nitric oxide (NO) in the renal haemodynamic and excretory responses to ischaemia-reperfusion both normally and in the hypertensive state by chronic administration of cyclo-oxygenase (COX) inhibitors." | 1.35 | Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation. ( Johns, EJ; Knight, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santos-Galdiano, M | 1 |
| Pérez-Rodríguez, D | 1 |
| Anuncibay-Soto, B | 1 |
| Font-Belmonte, E | 1 |
| Ugidos, IF | 1 |
| Pérez-García, CC | 1 |
| Fernández-López, A | 1 |
| Kinra, M | 1 |
| Arora, D | 1 |
| Mudgal, J | 1 |
| Pai, KSR | 1 |
| Mallikarjuna Rao, C | 1 |
| Nampoothiri, M | 1 |
| Luca, MC | 2 |
| Liuni, A | 2 |
| McLaughlin, K | 1 |
| Gori, T | 2 |
| Parker, JD | 2 |
| Senbel, AM | 2 |
| AbdelMoneim, L | 1 |
| Omar, AG | 2 |
| Abdel-Moneim, LM | 1 |
| Mohamed, HF | 1 |
| Daabees, TT | 1 |
| Abdel-Gaber, SA | 1 |
| Ibrahim, MA | 1 |
| Amin, EF | 1 |
| Ibrahim, SA | 1 |
| Mohammed, RK | 1 |
| Abdelrahman, AM | 1 |
| Farag, MM | 1 |
| Khalifa, AA | 1 |
| Elhadidy, WF | 1 |
| Rashad, RM | 1 |
| Malek, HA | 1 |
| Saleh, DM | 1 |
| Sakai, Y | 1 |
| Tanaka, T | 1 |
| Seki, M | 1 |
| Okuyama, S | 1 |
| Fukuchi, T | 1 |
| Yamagata, K | 1 |
| Takei, N | 1 |
| Nawa, H | 1 |
| Abe, H | 1 |
| Peskar, BM | 2 |
| Ehrlich, K | 2 |
| Schuligoi, R | 2 |
| Peskar, BA | 2 |
| Gaur, V | 1 |
| Kumar, A | 1 |
| Abd El-Aal, SA | 1 |
| El-Sawalhi, MM | 1 |
| Seif-El-Nasr, M | 1 |
| Kenawy, SA | 1 |
| Shafiq, N | 1 |
| Malhotra, S | 1 |
| Pandhi, P | 1 |
| Nada, R | 1 |
| Knight, S | 1 |
| Johns, EJ | 1 |
| Lozano, H | 1 |
| Wu, D | 1 |
| Bassuk, J | 1 |
| Aria, J | 1 |
| Kurlansky, P | 1 |
| Lamas, GA | 1 |
| Adams, JA | 1 |
| Fromm, RE | 1 |
| Varon, J | 1 |
| Hamada, T | 1 |
| Tsuchihashi, S | 1 |
| Avanesyan, A | 1 |
| Duarte, S | 1 |
| Moore, C | 1 |
| Busuttil, RW | 1 |
| Coito, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Remote Ischaemic Conditioning on Blood Pressure Control in Patients With Chronic Kidney Disease - the ERIC-BP-CKD Trial[NCT03236350] | 85 participants (Anticipated) | Interventional | 2017-11-28 | Recruiting | |||
| A Randomized, Single-blinded Placebo-controlled Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)[NCT02506062] | 21 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Reperfusion Injury
| Article | Year |
|---|---|
Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study.
Topics: Adult; Analysis of Variance; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2013 |
Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study.
Topics: Adult; Analysis of Variance; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2013 |
Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study.
Topics: Adult; Analysis of Variance; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2013 |
Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study.
Topics: Adult; Analysis of Variance; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2013 |
Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study.
Topics: Adolescent; Adult; Analysis of Variance; Blood Flow Velocity; Celecoxib; Cyclooxygenase 2 Inhibitors | 2012 |
17 other studies available for celecoxib and Reperfusion Injury
| Article | Year |
|---|---|
Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion.
Topics: Animals; Astrocytes; Celecoxib; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Ne | 2018 |
Effect of Caffeic Acid on Ischemia-Reperfusion-Induced Acute Renal Failure in Rats.
Topics: Acute Kidney Injury; Animals; Antioxidants; Arachidonate 5-Lipoxygenase; Blood Urea Nitrogen; Caffei | 2019 |
Celecoxib modulates nitric oxide and reactive oxygen species in kidney ischemia/reperfusion injury and rat aorta model of hypoxia/reoxygenation.
Topics: Animals; Aorta; Celecoxib; Cell Hypoxia; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Endothelium, | 2014 |
Evaluation of l-arginine on kidney function and vascular reactivity following ischemic injury in rats: protective effects and potential interactions.
Topics: Acetylcholine; Acute Kidney Injury; Animals; Antioxidants; Aorta; Arginine; Ascorbic Acid; Celecoxib | 2014 |
Effect of selective versus non-selective cyclooxygenase inhibitors on ischemia-reperfusion-induced hepatic injury in rats.
Topics: Alanine Transaminase; Animals; Caspase 3; Celecoxib; Cyclooxygenase 2 Inhibitors; Gene Expression Re | 2015 |
Hepatorenal protection in renal ischemia/reperfusion by celecoxib and pentoxifylline.
Topics: Animals; Biomarkers; Celecoxib; Drug Administration Schedule; Drug Therapy, Combination; Kidney; Kid | 2016 |
Cyclooxygenase-2 inhibitor celecoxib in a rat model of hindlimb ischemia reperfusion.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Glutathione; Hindlimb; Lung; Male; Oxidative Stress | 2009 |
Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice.
Topics: Animals; Celecoxib; Cell Death; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Green Fluorescent Pro | 2009 |
Role of lipoxygenases and the lipoxin A(4)/annexin 1 receptor in ischemia-reperfusion-induced gastric mucosal damage in rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Animals; Annexins; Anti-Ulcer Agents; Celecoxib; Cycloox | 2009 |
Role of lipoxygenases and lipoxin A(4)/annexin-1 receptor in gastric protection induced by 20% ethanol or sodium salicylate in rats.
Topics: Acetamides; Animals; Annexins; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; De | 2009 |
Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2 Inhibitors; Glutathione | 2012 |
Effect of celecoxib and L-NAME on global ischemia-reperfusion injury in the rat hippocampus.
Topics: Animals; Caspase 3; Celecoxib; Cyclooxygenase 2 Inhibitors; Hippocampus; Neuroprotective Agents; NG- | 2013 |
Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors.
Topics: Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Gastric Mucosa; Gastrointestinal Tract; Indo | 2005 |
Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Topics: Animals; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 In | 2008 |
The effects of prostaglandin inhibition on whole-body ischemia-reperfusion in swine.
Topics: Animals; Cardiopulmonary Resuscitation; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Disease | 2008 |
Prostaglandin inhibition and ischemia: where are the data?
Topics: Animals; Cardiopulmonary Resuscitation; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal | 2008 |
Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury.
Topics: Animals; bcl-X Protein; Celecoxib; Chemokine CXCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2008 |